Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 44Hodgkin Disease 8Neoplasm Metastasis 6Neoplasms 5Leiomyosarcoma 5Skin Neoplasms 4Lymphoma 4Uveal Melanoma 3Sarcoma 3Hematologic Diseases 2Solid Tumor 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Liposarcoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Neoplasms 1Advanced Melanoma 1

Interventions

olaparib 1Dacarbazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma Neoplasms × Dacarbazine × Clear all
NCT00516802 2009-05-15

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

AstraZeneca

Phase 1 Completed
40 enrolled
Dermatologic

Melanoma Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡